Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-28T17:02:08.465Z Has data issue: false hasContentIssue false

Primary non-Hodgkin’s lymphoma of the orbit: treatment outcomes from India

Published online by Cambridge University Press:  06 January 2022

Budhi Singh Yadav*
Affiliation:
Post Graduate Institute of Medical Education and Research, Radiotherapy & Oncology, Chandigarh, India
Vjai Simha
Affiliation:
Post Graduate Institute of Medical Education and Research, Radiotherapy & Oncology, Chandigarh, India
*
Author for correspondence: Budhi Singh Yadav, Post Graduate Institute of Medical Education and Research, Radiotherapy & Oncology, Chandigarh, India. E-mail: drbudhi@gmail.com

Abstract

Background:

Primary non-Hodgkin’s lymphoma (NHL) of the orbit is rare. Orbital NHLs show good response to both radiotherapy (RT) and chemotherapy, and hence, the emphasis should be to ensure maximum cure rate with minimum morbidity. In this study, we present the clinical profile and treatment outcomes of patients with NHL who had initial presentation in the orbit.

Materials and methods:

In this retrospective analysis, case records of patients with a diagnosis of NHL of the orbit were analysed from January 2005 to January 2015. Patients were worked up and staged according to the Ann Arbor system. Patients with large tumours were initially given chemotherapy with CHOP regimen (cyclophosphamide, vincristine, adriamycin and prednisolone) three weekly for 4–6 cycles. Patients with residual disease were given RT 20–30 Gy at 2 Gy per fraction. RT when given as a primary treatment consisted of 36–45 Gy at 1·8–2 Gy per fraction on either Cobalt 60 machine or linear accelerator.

Results:

A total of 52 patients with diagnosis of orbital NHL were included in this study. Median age at presentation was 57 years (range 13–71). Left, right and bilateral orbit was involved in 21 (40%), 28(54%) and 3(6%) patients, respectively. Low- and high-grade pathology was seen in 39(75%) and 13(25%) patients, respectively. On immunohistochemistry, 23(44%) tumors were CD 20 positive. After staging, 33 (63%) patients had stage I disease. Median tumour size was 4·0 × 3·2 × 1·5 cm (1·7 × 1·7 × 1·4 cm to 5·8 × 4·0 × 4·7 cm). Primary RT was given to 7(13%) patients. Upfront chemotherapy was given in 45(86·5%) patients, out of which 24 had stage I disease. RT consolidation was done in 26 (50%) patients for residual disease after chemotherapy. Median follow-up was 88 months (range 29–183 months). Relapse occurred in 6(9·6%) patients; 2 local; 2 local + distant and in 2 distant alone. These patients were successfully salvaged with systemic chemotherapy and local RT. One patient died due to neutropenia. Overall survival in this series was 96%.

Conclusions:

Excellent local control was achieved with initial chemotherapy followed by RT for primary orbital NHL with minimal toxicity. We recommend a dose of 36–40 Gy for definitive RT and 30 Gy for lymphoma following chemotherapy using 2 Gy/fraction for Indian patients who present with bulky tumours. RT should be incorporated in treatment of orbital NHL whenever possible as it is safe, effective and is associated with minimal complications.

Type
Original Article
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bolek, TW, Moyses, HM, Marcus, RB, Jr., et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999; 44 (1): 3136.CrossRefGoogle ScholarPubMed
Stefanovic, A, Lossos, IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood 2009; 114 (3): 501510.CrossRefGoogle ScholarPubMed
Flanders, AE, Espinosa, GA, Markiewicz, DA, et al. Orbital lymphoma. Role of CT and MRI. Radiol Clin North Am 1987; 25 (3): 601613.CrossRefGoogle ScholarPubMed
Makepeace, AR, Fermont, DC, Bennett, MH. Primary non-Hodgkin’s lymphoma of the orbit. J R Soc Med 1988; 81 (11): 640642.CrossRefGoogle ScholarPubMed
Reddy, EK, Bhatia, P, Evans, RG. Primary orbital lymphomas. Int J Radiat Oncol Biol Phys 1988; 15 (5): 12391241.CrossRefGoogle ScholarPubMed
Letschert, JG, Gonzalez Gonzalez, D, Oskam, J, et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin’s lymphoma. Radiother Oncol. 1991; 22 (1): 3644.CrossRefGoogle Scholar
Stafford, SL, Kozelsky, TF, Garrity, JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001; 59 (2): 139144.Google ScholarPubMed
Martinet, S, Ozsahin, M, Belkacemi, Y, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55 (4): 892898.Google Scholar
Minehan, KJ, Martenson, JA, Jr., Garrity, JA, et al. Local control and complications after radiation therapy for primary orbital lymphoma: a case for low-dose treatment. Int J Radiat Oncol Biol Phys 1991; 20 (4): 791796.CrossRefGoogle ScholarPubMed
Chao, CKS, Lin, H-S, Rao Devineni, V, et al. Radiation therapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 1995; 31 (4): 929934.CrossRefGoogle Scholar
Ben Simon, GJ, Cheung, N, McKelvie, P, et al. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006; 113 (7): 12091213.CrossRefGoogle ScholarPubMed
Galieni, P, Polito, E, Leccisotti, A, et al. Localized orbital lymphoma. Haematologica 1997; 82 (4): 436439.Google ScholarPubMed
Hatef, E, Roberts, D, McLaughlin, P, et al. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol 2007; 125 (12): 16631667.CrossRefGoogle ScholarPubMed
Polito, E, Galieni, P, Leccisotti, A. Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefes Arch Clin Exp Ophthalmol 1996; 234 (8): 504509.CrossRefGoogle ScholarPubMed
Roe, RH, Finger, PT, Kurli, M, et al. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology 2006; 113 (10): 18541858.CrossRefGoogle Scholar
Ilica, AT, Kocacelebi, K, Savas, R, et al. Imaging of extranodal lymphoma with PET/CT. Clin Nucl Med 2011; 36 (10): e127e138.CrossRefGoogle ScholarPubMed
Eckardt, AM, Lemound, J, Rana, M, et al. Orbital lymphoma: diagnostic approach and treatment outcome. World J Surg Oncol 2013; 11: 73.CrossRefGoogle ScholarPubMed
Bhatia, S, Paulino, AC, Buatti, JM, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54 (3): 818823.CrossRefGoogle ScholarPubMed
Zhou, P, Andrea, K, Silver, B, et al. Radiation therapy for orbital lymphoma. Int J Radiat Oncol Biol Phys 2005; 63: 866871.CrossRefGoogle ScholarPubMed
Yadav, BS, Sharma, SC. Orbital lymphoma: role of radiation. Indian J Ophthalmol 2009; 57 (2): 9197.Google ScholarPubMed
Yadav, BS, Sastri, GJ, Nalini, G, Gunaseelan, K, Sharma, SC. Primary localized high-grade lymphoma of the lacrimal gland. Asian J Opthalmol 2007; 9: 3235.Google Scholar